Mitchell Geffner
Pediatric Endocrinology · Los Angeles, CANPI 1043302391
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,393 of the $129,438 with a category attached, or 63.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.2%. Reporting peaked in 2023 at $31,948 and has fallen 65.2% since, to $11,116 in 2025. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $803.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eton Pharmaceuticals, Inc.$28K
- Novo Nordisk$23K
- Pfizer$22K
- Ascendis Pharma Endocrinology Inc$19K
- Neurocrine Biosciences, Inc.$17K
- Hexal AG$8K
- plus $15K from 9 others
Across 438 payments — averaging $498.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$148K
- Pfizer$28K
- Ascendis Pharma Endocrinology Inc$26K
- Antares Pharma, Inc.$15K
- Neurocrine Biosciences, Inc.$1K
- Endo Pharmaceuticals Inc.$40
What the payments were for
- Consulting fees$82,39364%
- Speaking & faculty fees$23,70618%
- Travel & lodging$8,4307%
- Food & beverage$14,87911%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eton Pharmaceuticals, Inc. | 4 | $27,505 |
| Novo Nordisk | 55 | $22,781 |
| Pfizer | 15 | $21,595 |
| Ascendis Pharma Endocrinology Inc | 12 | $18,595 |
| Neurocrine Biosciences, Inc. | 29 | $16,573 |
| Hexal AG | 6 | $7,765 |
| Ferring Pharmaceuticals Inc. | 14 | $5,190 |
| Daiichi Sankyo Inc. | 3 | $2,975 |
| Tolmar, Inc. | 6 | $2,564 |
| Endo Pharmaceuticals Inc. | 2 | $1,504 |
| Tolmar Pharmaceuticals, Inc. | 7 | $1,150 |
| Theratechnologies Inc. | 1 | $750 |
| AbbVie | 3 | $259 |
| Biomarin Pharmaceutical Inc. | 3 | $231 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Alkindi$27,505
- SKYTROFA$18,464
- Norditropin$11,153
- GENOTROPIN$9,303
- Sogroya$8,802
- NGENLA$6,383
- ZOMACTON$4,802
- FENSOLVI$3,498
- Welchol$2,975
- CRENESSITY$2,626
- KHINDIVI$1,651
- INCRELEX$1,651
- SUPPRELIN$1,480
- Macrilen$349
- Lupron Depot$244
- Vimizim$107
How this compares
$129,438 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Los Angeles
- Francine KaufmanLos Angeles$184K
- Alaina VidmarLos Angeles$29K
- Nancy ChangLos Angeles$14K
- Roshanak MonzaviLos Angeles$9K
- Christina RehLos Angeles$6K
- Lily ChaoLos Angeles$6K
- John ChingLos Angeles$4K
- Steven MittelmanLos Angeles$4K
- Pinchas CohenLos Angeles$3K
- Apisadaporn ThambunditLos Angeles$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.